Welcome to our dedicated page for GRAY news (Ticker: GRAY), a resource for investors and traders seeking the latest updates and insights on GRAY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GRAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GRAY's position in the market.
Graybug Vision, Inc. (Nasdaq: GRAY) announced the appointment of Dirk Sauer, PhD, to its Board of Directors effective April 13, 2022. He replaces Gerald Cagle, PhD, who is retiring after eight years but will remain as an advisor. Sauer brings over 30 years of experience in ophthalmic drug development, and he will lead the Science and Innovation Committee to guide the company's research and development strategies. Graybug focuses on innovative treatments for ocular diseases, with candidates like GB-102 for wet AMD and GB-401 for glaucoma.
Graybug Vision, Inc. (Nasdaq: GRAY) announced key updates on its clinical pipeline aimed at ocular diseases. The Phase 2 trial for GB-102 in wet AMD is set for Q4 2022, while a Phase 1 trial for glaucoma (GB-401) is anticipated in Q1 2023. Additionally, the acquisition of a corneal gene therapy program (GB-501) is underway, with data expected in Q4 2023. Current cash is projected to sustain operations into Q4 2023. A virtual Investor R&D Day is scheduled for March 30, 2022, to present these developments.
Graybug Vision, Inc. (NASDAQ: GRAY) will host a virtual Investor R&D Day on March 30, 2022, from 11 a.m. to 12:45 p.m. ET. The event will feature expert presentations on ocular diseases, including wet age-related macular degeneration and primary open-angle glaucoma. Graybug aims to provide insights into its advancing pipeline and drug discovery programs, focusing on new assets in inherited corneal and retinal diseases. Registration is available through the company’s website, and participants can join via phone. Graybug is dedicated to developing transformative ocular disease treatments.
Graybug Vision, Inc. (NASDAQ: GRAY) reported a net loss of $35.8 million for 2021, up from $27.5 million in 2020. R&D expenses decreased to $18.9 million from $21.0 million, while general and administrative expenses rose notably to $17.0 million. Key advancements include the completion of the ALTISSIMO Phase 2b trial for GB-102, demonstrating a six-month treatment duration in 48% of patients. The company is preparing for a new Phase 2 trial and aims to initiate the GB-401 Phase 1 trial in 2023. The upcoming R&D Day is scheduled for March 30, 2022.
Graybug Vision, Inc. (Nasdaq: GRAY) announced participation in three key medical and investor conferences. On February 11, 2022, Dr. Veeral Sheth will present on GB-102's safety/durability in treating wet age-related macular degeneration. Fred Guerard will discuss advances in GB-401 for glaucoma during the New Horizons Forum on the same day. Additionally, Guerard will partake in a fireside chat at the SVB Leerink Global Healthcare Conference on February 17, 2022. Graybug is dedicated to developing innovative treatments for retinal and optic nerve diseases, with a focus on extended drug delivery technologies.
Graybug Vision, Inc. (NASDAQ: GRAY) announced the hiring of six new employees to bolster its Research & Development, Regulatory Affairs, and Program Management teams. CEO Fred Guerard emphasized the importance of expanding their ophthalmology team to enhance their clinical pipeline in 2022. Key hires include Fang Li, VP of Regulatory Affairs, and Ali Kakavand, VP of Program Management, both bringing over 20 years of relevant experience. Additionally, the company granted inducement options for 234,200 shares at an exercise price of $1.55, aligned with its strategic growth initiatives.
Graybug Vision, a clinical-stage biopharmaceutical company focused on retinal and optic nerve diseases, announced that CEO Fred Guerard will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The chat will be available on November 22, 2021, at 10 a.m. ET. Investors can also schedule 1x1 meetings through Piper Sandler. Graybug's lead candidate, GB-102, targets retinal diseases with a six-month or longer dosing regimen, while GB-401 is aimed at glaucoma treatments. For more details, visit Graybug's website.
Graybug Vision, Inc. (NASDAQ: GRAY) reported its financial results for the three and nine months ended September 30, 2021, revealing a net loss of $8.0 million for Q3 2021, up from $4.7 million in Q3 2020. R&D expenses decreased to $4.0 million, while G&A expenses rose to $4.0 million. For the nine-month period, the net loss was $27.1 million, compared to $18.4 million in 2020. The company is advancing its GB-102 wet AMD treatments and holds $72.6 million in cash, expected to fund operations into 2023.
BALTIMORE, Nov. 01, 2021 - Graybug Vision (Nasdaq: GRAY) announced two key clinical data presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting, scheduled for November 12-15 in New Orleans. The CEO, Fred Guerard, will present a company overview at the Eyecelerator@AAO event on November 11, while Dr. Arshad Khanani will share findings on the safety and durability of GB-102 for wet age-related macular degeneration. Additionally, Dr. Veeral Sheth will discuss GB-102's late-breaking results at the Retina Subspecialty Day on November 13.
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard's participation at the Ophthalmology Innovation Summit (OIS) Retina on October 7, 2021, in San Antonio, Texas. He will present at the "Innovation Showcase" at 11:05 a.m. ET and participate in the "Finding and Funding Assets in Retina" panel at 4:55 p.m. ET. Graybug focuses on transformative medicines for retinal diseases, with its lead candidate, GB-102, targeting prolonged dosing regimens to improve treatment outcomes.
FAQ
What is the market cap of GRAY (GRAY)?
